Vertex Pharma Earnings: Revenue Slips After Increasing Four Quarters in a Row

Google+ | + More Articles
  • Like on Facebook
  • Share on Google+
  • Share on LinkedIn

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) reported its results for the third quarter. Vertex Pharmaceuticals is engaged in the business of discovering, developing and commercializing small molecule drugs for the treatment of serious diseases.

Earnings season is back and more important than ever. Get our newest CHEAT SHEET stock picks now

Vertex Pharmaceuticals Incorporated Earnings Cheat Sheet

Results: Reported a loss of $57.5 million (27 cents per diluted share) in the quarter. The medical-bioengineering had net income of $221.1 million or $1.02 per share in the year-earlier quarter.

Revenue: Fell 49% to $336 million from the year-earlier quarter.

Actual vs. Wall St. Expectations: Vertex Pharmaceuticals Incorporated reported adjusted net income of 13 cents per share. By that measure, the company fell short of mean estimate of 19 cents per share. It fell short of the average revenue estimate of $480.8 million.

Quoting Management: “In the third quarter, we made significant progress across our broad pipeline of potential medicines,” said Jeffrey Leiden, M.D., Ph.D., Chair, President and Chief Executive Officer of Vertex. “In hepatitis C, we are advancing rapidly with our plans to evaluate multiple all-oral regimens of VX-135, both with medicines in our own pipeline and, as we announced earlier today, in collaboration with other companies. We are also advancing toward our goal to help more people with cystic fibrosis with the recent initiation of multiple label-expansion studies for ivacaftor and the planned start of pivotal development early next year for a combination of VX-809 and ivacaftor. Importantly, we are advancing our business while keeping a focus on financial discipline and prioritization to allow us to continue investing in key research and development programs that may produce transformative medicines for patients in the years to come,” concluded Dr. Leiden.

Key Stats:

A year-over-year revenue decrease last quarter snaps a streak of four consecutive quarters of revenue increases. The best quarter in that span was the third quarter of the last fiscal year, which saw revenue rise 2670.3%.

The company has now come in under analyst forecasts for three quarters in a row. It missed the mark by 24 cents in the second quarter and by 15 cents in the first quarter.

Looking Forward: Analysts are pessimistic about the company’s results for the next quarter. The average estimate has fallen for the fourth quarter to 13 cents per share, down from 14 cents seven days ago. For the fiscal year, the average estimate has moved up from 56 cents a share to 66 cents over the last ninety days.

Stocks with improving earnings metrics are worthy of your extra attention. In fact, “E = Earnings Are Increasing Quarter-Over-Quarter” is a core component of our CHEAT SHEET investing framework for this very reason. Don’t waste another minute — click here and get our CHEAT SHEET stock picks now.

(Company fundamentals provided by Xignite Financials. Earnings estimates provided by Zacks)

Don’t Miss These Additional Hot Stories:

Is Ford’s Stock a Buy After a Record Quarter?

Will Sirius’s Stock Still Be a Buy After the Buyout?

Is Facebook Harmful to Your Health and Wallet?

More Articles About:

To contact the reporter on this story: staff.writers@wallstcheatsheet.com To contact the editor responsible for this story: editors@wallstcheatsheet.com

Yahoo Finance, Harvard Business Review, Market Watch, The Wall St. Journal, Financial Times, CNN Money, Fox Business